

Revolutionary therapy by Mileutis to enhance dairy cows health and milk quality

11 August 2023 | News

Imilac, therapy to completely substitute the routine use of antibiotics at dry-off in the dairy industry

Mileutis Clinical Trial Highlights

IMILAC™

A Robust, **Antibiotic-free**, Hormone-free, Breakthrough in Dry Cow Therapy, Further Enhancing Milk Quality.

PROTEIN
IMILAC™ Treated Cows Produce Milk With 7.2% More Protein

FAT
IMILAC™ Treated Cows Produce Milk With 4% More Fat

957kg
An Annual Increase in the Subsequent Lactation of 957kg of Milk* Per Cow of Nutritionally Superior Milk

236 kg
Extra Milking Days by Shortening the Dry-off Period Leads to a Gain of 236 kg Per Cow Per Year

IMILAC™
Dry Cow Intramammary Suspension for Cattle

Amounts to be administered, administration route, indications for use and special precautions for use, please refer to the package leaflet. Withdrawal period: none. Storage and transport: Frozen (-17°C to -25°C). For veterinary use only | Keep out of reach of children.

Mileutis

Imilac, therapy to completely substitute the routine use of antibiotics at dry-off in the dairy industry

Mileutis, an Israeli-based biopharmaceutical company conducted clinical trials in seven large Israeli dairy farms, in collaboration with Strauss Health (partially owned by Groupe Danone), demonstrated that Mileutis can effectively substitute the major use of antibiotics in the dairy industry.

Milk derived from cows treated with Mileutis' Imilac non-antibiotic, non-hormonal therapy exhibited a 7.2% increase in protein content, 4% increase in fat content, and an increase of 957 kg (8.6%) in energy corrected milk yield per cow over 305 days. The trial paves the way for superior milk production performance for dairy farmers while improving the well-being of the dairy cows.

Designed to replace the routine use of antibiotics administered at dry-off once a year, Imilac has exhibited game-changing results in the clinical trials, paving the way for a transformation in the dairy sector and leading the dairy industry into a sustainable future.

In addition, the study revealed that Imilac is further impacting milk nutritional characteristics a breakthrough that was patented by Mileutis. The trial was carried out in dairy farms providing milk to Israel's two largest dairy product providers a Yotvata Dairy, part of the Strauss Health Group, partially owned by Danone, and Tnuva, Israel's largest dairy company.

David Javier Iscovich, CEO and co-founder of Mileutis: "Consumers can anticipate a future where they will enjoy better milk, produced by healthier cows, and with superior nutritional values".

Mileutis is leading the dairy industry and animal health into a sustainable future, has completed a rigorous, randomized, case-controlled, multi-center, clinical field trial. The trial was conducted at seven different commercial dairy farms and involved over 500 dairy cows. The results of this trial provide further conclusive evidence of the ability of Imilacâ?, therapy to completely substitute the routine use of antibiotics at dry-off in the dairy industry.